Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation

Toby C. Trujillo, Paul P. Dobesh, George H. Crossley, Shannon W. Finks

Research output: Contribution to journalReview article

Abstract

As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) have continued to be incorporated into clinical practice for long-term anticoagulation for AF, experience with how best to manage use of DOACs during electrophysiologic procedures is evolving. This review is intended to provide health care providers with a summary of current evidence regarding the use of DOACs during cardioversion and catheter ablation and provide key considerations for their use during such electrophysiologic procedures. PubMed and MEDLINE were searched from inception through June 2018 for studies in humans comparing DOACs alone or against vitamin K antagonists (VKAs) in adult patients (> 18 yrs) who underwent cardioversion or AF catheter ablation using the following key words: “rivaroxaban,” “dabigatran,” “apixaban,” “edoxaban,” “non–vitamin K antagonists,” “direct or new oral anticoagulants,” “warfarin,” “vitamin K antagonists,” “cardioversion,” “ablation of atrial fibrillation,” “uninterrupted,” and “catheter ablation.” Four retrospective studies and three prospective trials comparing DOACs with VKA in patients undergoing cardioversion and three prospective studies in patients undergoing catheter ablation for AF were identified. Observational data and meta-analyses were also critically reviewed. Prospective trials to date suggest similar efficacy and safety with using DOACs in the setting of cardioversion and AF ablation compared to traditional therapy with VKA, with or without bridging. Injectable anticoagulant overlap can be avoided in patients receiving DOACs in the setting of cardioversion for AF. Minimal interruption in anticoagulation may be only necessary for AF ablation in those with highest bleeding risk, such as in renal dysfunction and where drug-drug interactions may increase risk for anticoagulant accumulation. Periprocedural advantages of DOACs include convenience, rapid and predictable onset of effect, improved patient satisfaction, and potential for reduced costs.

Original languageEnglish (US)
Pages (from-to)94-108
Number of pages15
JournalPharmacotherapy
Volume39
Issue number1
DOIs
StatePublished - Jan 2019

Fingerprint

Electric Countershock
Anticoagulants
Atrial Fibrillation
Catheter Ablation
Vitamin K
Warfarin
Patient Satisfaction
Drug Interactions
PubMed
MEDLINE
Health Personnel
Meta-Analysis
Retrospective Studies
Prospective Studies
Hemorrhage

Keywords

  • ablation
  • cardioversion
  • direct oral anticoagulants
  • electrophysiology procedures

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. / Trujillo, Toby C.; Dobesh, Paul P.; Crossley, George H.; Finks, Shannon W.

In: Pharmacotherapy, Vol. 39, No. 1, 01.2019, p. 94-108.

Research output: Contribution to journalReview article

Trujillo, Toby C. ; Dobesh, Paul P. ; Crossley, George H. ; Finks, Shannon W. / Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. In: Pharmacotherapy. 2019 ; Vol. 39, No. 1. pp. 94-108.
@article{a3f61243e8594e5ebdc77a61744109ae,
title = "Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation",
abstract = "As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) have continued to be incorporated into clinical practice for long-term anticoagulation for AF, experience with how best to manage use of DOACs during electrophysiologic procedures is evolving. This review is intended to provide health care providers with a summary of current evidence regarding the use of DOACs during cardioversion and catheter ablation and provide key considerations for their use during such electrophysiologic procedures. PubMed and MEDLINE were searched from inception through June 2018 for studies in humans comparing DOACs alone or against vitamin K antagonists (VKAs) in adult patients (> 18 yrs) who underwent cardioversion or AF catheter ablation using the following key words: “rivaroxaban,” “dabigatran,” “apixaban,” “edoxaban,” “non–vitamin K antagonists,” “direct or new oral anticoagulants,” “warfarin,” “vitamin K antagonists,” “cardioversion,” “ablation of atrial fibrillation,” “uninterrupted,” and “catheter ablation.” Four retrospective studies and three prospective trials comparing DOACs with VKA in patients undergoing cardioversion and three prospective studies in patients undergoing catheter ablation for AF were identified. Observational data and meta-analyses were also critically reviewed. Prospective trials to date suggest similar efficacy and safety with using DOACs in the setting of cardioversion and AF ablation compared to traditional therapy with VKA, with or without bridging. Injectable anticoagulant overlap can be avoided in patients receiving DOACs in the setting of cardioversion for AF. Minimal interruption in anticoagulation may be only necessary for AF ablation in those with highest bleeding risk, such as in renal dysfunction and where drug-drug interactions may increase risk for anticoagulant accumulation. Periprocedural advantages of DOACs include convenience, rapid and predictable onset of effect, improved patient satisfaction, and potential for reduced costs.",
keywords = "ablation, cardioversion, direct oral anticoagulants, electrophysiology procedures",
author = "Trujillo, {Toby C.} and Dobesh, {Paul P.} and Crossley, {George H.} and Finks, {Shannon W.}",
year = "2019",
month = "1",
doi = "10.1002/phar.2205",
language = "English (US)",
volume = "39",
pages = "94--108",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation

AU - Trujillo, Toby C.

AU - Dobesh, Paul P.

AU - Crossley, George H.

AU - Finks, Shannon W.

PY - 2019/1

Y1 - 2019/1

N2 - As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) have continued to be incorporated into clinical practice for long-term anticoagulation for AF, experience with how best to manage use of DOACs during electrophysiologic procedures is evolving. This review is intended to provide health care providers with a summary of current evidence regarding the use of DOACs during cardioversion and catheter ablation and provide key considerations for their use during such electrophysiologic procedures. PubMed and MEDLINE were searched from inception through June 2018 for studies in humans comparing DOACs alone or against vitamin K antagonists (VKAs) in adult patients (> 18 yrs) who underwent cardioversion or AF catheter ablation using the following key words: “rivaroxaban,” “dabigatran,” “apixaban,” “edoxaban,” “non–vitamin K antagonists,” “direct or new oral anticoagulants,” “warfarin,” “vitamin K antagonists,” “cardioversion,” “ablation of atrial fibrillation,” “uninterrupted,” and “catheter ablation.” Four retrospective studies and three prospective trials comparing DOACs with VKA in patients undergoing cardioversion and three prospective studies in patients undergoing catheter ablation for AF were identified. Observational data and meta-analyses were also critically reviewed. Prospective trials to date suggest similar efficacy and safety with using DOACs in the setting of cardioversion and AF ablation compared to traditional therapy with VKA, with or without bridging. Injectable anticoagulant overlap can be avoided in patients receiving DOACs in the setting of cardioversion for AF. Minimal interruption in anticoagulation may be only necessary for AF ablation in those with highest bleeding risk, such as in renal dysfunction and where drug-drug interactions may increase risk for anticoagulant accumulation. Periprocedural advantages of DOACs include convenience, rapid and predictable onset of effect, improved patient satisfaction, and potential for reduced costs.

AB - As overall prevalence of atrial fibrillation (AF) continues to rise, the number of patients who undergo ablation, or electrical/chemical cardioversion, to restore normal sinus rhythm continues to increase as well. As direct oral anticoagulants (DOACs) have continued to be incorporated into clinical practice for long-term anticoagulation for AF, experience with how best to manage use of DOACs during electrophysiologic procedures is evolving. This review is intended to provide health care providers with a summary of current evidence regarding the use of DOACs during cardioversion and catheter ablation and provide key considerations for their use during such electrophysiologic procedures. PubMed and MEDLINE were searched from inception through June 2018 for studies in humans comparing DOACs alone or against vitamin K antagonists (VKAs) in adult patients (> 18 yrs) who underwent cardioversion or AF catheter ablation using the following key words: “rivaroxaban,” “dabigatran,” “apixaban,” “edoxaban,” “non–vitamin K antagonists,” “direct or new oral anticoagulants,” “warfarin,” “vitamin K antagonists,” “cardioversion,” “ablation of atrial fibrillation,” “uninterrupted,” and “catheter ablation.” Four retrospective studies and three prospective trials comparing DOACs with VKA in patients undergoing cardioversion and three prospective studies in patients undergoing catheter ablation for AF were identified. Observational data and meta-analyses were also critically reviewed. Prospective trials to date suggest similar efficacy and safety with using DOACs in the setting of cardioversion and AF ablation compared to traditional therapy with VKA, with or without bridging. Injectable anticoagulant overlap can be avoided in patients receiving DOACs in the setting of cardioversion for AF. Minimal interruption in anticoagulation may be only necessary for AF ablation in those with highest bleeding risk, such as in renal dysfunction and where drug-drug interactions may increase risk for anticoagulant accumulation. Periprocedural advantages of DOACs include convenience, rapid and predictable onset of effect, improved patient satisfaction, and potential for reduced costs.

KW - ablation

KW - cardioversion

KW - direct oral anticoagulants

KW - electrophysiology procedures

UR - http://www.scopus.com/inward/record.url?scp=85060942763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060942763&partnerID=8YFLogxK

U2 - 10.1002/phar.2205

DO - 10.1002/phar.2205

M3 - Review article

C2 - 30548542

AN - SCOPUS:85060942763

VL - 39

SP - 94

EP - 108

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 1

ER -